Home › Research › Disease mechanisms
Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer’s disease
Prabhakar Tiwari, Anu Gupta, Meenakshi Kaushik, Anjali Yadav, Anjali Anjali, Rekha Dwivedi, Pallavi Mudgal, Yashwant Kumar et al.. Brain Communications, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Clinical Dementia Rating-Global scores (1.44 ± 0.65 versus 0.24 ± 0.25; P < 0.0001) and Patient Health Questionnaire-9 scores (4.88 ± 4.21 versus 0.20 ± 0.50; P < 0.0001) were higher than controls. Principal component analysis revealed distinct metabolic clustering with 75 altered metabolites. Biomarker analysis revealed elevated amyloid beta 40, amyloid beta 42/40 ratio, phosphorylated tau181, phosphorylated tau217, phosphorylated tau217/amyloid beta 42 ratio, neurofilament light chain, APOE4, C-reactive protein, and 8-hydroxy-2′-deoxyguanosine, with reduced brain-derived neurotrophic factor (all P < 0.05). Significant correlations included eupatilin with phosphorylated tau217 and 8-hydroxy-2′-deoxyguanosine, glyceraldehyde with brain-derived neurotrophic factor, guanine with APOE4, and valine inversely with phosphorylated tau181.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tiwari, P., Gupta, A., Kaushik, M., Yadav, A., Anjali, A., Dwivedi, R., et al. (2025). Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer’s disease. Brain Communications. https://doi.org/10.1093/braincomms/fcaf410
Vancouver
Tiwari P, Gupta A, Kaushik M, Yadav A, Anjali A, Dwivedi R, et al. Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer’s disease. Brain Communications. 2025. doi:10.1093/braincomms/fcaf410. PMID: 41229615.
BibTeX
@article{tiwari2025-41229615,
author = {Tiwari, Prabhakar and Gupta, Anu and Kaushik, Meenakshi and Yadav, Anjali and Anjali, Anjali and Dwivedi, Rekha and Mudgal, Pallavi and Kumar, Yashwant and others},
title = {{Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer’s disease}},
journal = {Brain Communications},
year = {2025},
doi = {10.1093/braincomms/fcaf410},
pmid = {41229615},
url = {https://doi.org/10.1093/braincomms/fcaf410}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Clinical Dementia Rating-Global scores (1.44 ± 0.65 versus 0.24 ± 0.25; P < 0.0001) and Patient Health Questionnaire-9 scores (4.88 ± 4.21 versus 0.20 ± 0.50; P < 0.0001) were higher than controls.
- Principal component analysis revealed distinct metabolic clustering with 75 altered metabolites.
- Biomarker analysis revealed elevated amyloid beta 40, amyloid beta 42/40 ratio, phosphorylated tau181, phosphorylated tau217, phosphorylated tau217/amyloid beta 42 ratio, neurofilament light chain, APOE4, C-reactive protein, and 8-hydroxy-2′-deoxyguanosine, with reduced brain-derived neurotrophic factor (all P < 0.05).
- Significant correlations included eupatilin with phosphorylated tau217 and 8-hydroxy-2′-deoxyguanosine, glyceraldehyde with brain-derived neurotrophic factor, guanine with APOE4, and valine inversely with phosphorylated tau181.
Why it matters
In a cross-sectional study, people with Alzheimer's disease showed distinct metabolic clustering with 75 altered metabolites and elevated markers including amyloid beta 40, phosphorylated tau181 and tau217, neurofilament light chain and APOE4, with reduced brain-derived neurotrophic factor. The authors present these as candidate biomarkers and pathways for early detection, not as a treatment or cure.
Study details
- Study designcross-sectional
- Participants25
- Effect sizeAUC = 0.917; AUC = 0.908; AUC = 0.858
- Evidence strengthModerate
How this study scored 51/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain Communications) |
| Journal's citation record | 0 / 4 | Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 25 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Rima Dada: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | All India Institute of Medical Sciences: institution h-index 440 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41229615) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1093/braincomms/fcaf410
- PubMed: 41229615
- Original source →
- Free full text: Brain Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Disease mechanisms
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.